INTRODUCTION: Directly observed therapy of highly active antiretroviral therapy (DOT-HAART) is a feasible adherence intervention. Prospective DOT-HAART studies have shown mixed results, and optimal target groups have yet to be defined. We performed a meta-analysis and systematic review to assess the effect of DOT-HAART on adherence and virologic and immunologic response. METHODS: We performed a comprehensive search through August 2009 to identify peer-reviewed controlled studies that involved outpatient DOT-HAART among adults and reported at least 1 outcome assessed in this meta-analysis. Random-effects meta-analyses were performed; differences in effect on virologic suppression were examined using stratified meta-analyses and meta-regression on several study characteristics. RESULTS: Seventeen studies met inclusion criteria. Compared with control groups, DOT-HAART recipients were more likely to achieve an undetectable viral load (random effects risk ratio 1.24, 95% confidence interval (CI): 1.08 to 1.41), a greater increase in CD4 cell count (random effects weighted mean difference 43 cells/microL, 95% CI: 12 to 74 cells/microL), and HAART adherence of > or =95% (random effects risk ratio 1.17, 95% CI: 1.03 to 1.32). Results varied with respect to virologic response. DOT-HAART did not have a significant effect on virologic suppression when restricted to randomized controlled studies. Post-treatment effect was not observed in a limited number of studies. CONCLUSIONS: DOT-HAART had a significant effect on virologic, immunologic, and adherence outcomes, although its efficacy was not supported when restricting analysis to randomized controlled trials. DOT-HAART shows greatest treatment effect when targeting individuals with greater risk of nonadherence and when delivering the intervention that maximizes participant convenience and provides enhanced adherence support. Further investigation is needed to assess the postintervention effect and cost-effectiveness of DOT-HAART.
INTRODUCTION: Directly observed therapy of highly active antiretroviral therapy (DOT-HAART) is a feasible adherence intervention. Prospective DOT-HAART studies have shown mixed results, and optimal target groups have yet to be defined. We performed a meta-analysis and systematic review to assess the effect of DOT-HAART on adherence and virologic and immunologic response. METHODS: We performed a comprehensive search through August 2009 to identify peer-reviewed controlled studies that involved outpatient DOT-HAART among adults and reported at least 1 outcome assessed in this meta-analysis. Random-effects meta-analyses were performed; differences in effect on virologic suppression were examined using stratified meta-analyses and meta-regression on several study characteristics. RESULTS: Seventeen studies met inclusion criteria. Compared with control groups, DOT-HAART recipients were more likely to achieve an undetectable viral load (random effects risk ratio 1.24, 95% confidence interval (CI): 1.08 to 1.41), a greater increase in CD4 cell count (random effects weighted mean difference 43 cells/microL, 95% CI: 12 to 74 cells/microL), and HAART adherence of > or =95% (random effects risk ratio 1.17, 95% CI: 1.03 to 1.32). Results varied with respect to virologic response. DOT-HAART did not have a significant effect on virologic suppression when restricted to randomized controlled studies. Post-treatment effect was not observed in a limited number of studies. CONCLUSIONS: DOT-HAART had a significant effect on virologic, immunologic, and adherence outcomes, although its efficacy was not supported when restricting analysis to randomized controlled trials. DOT-HAART shows greatest treatment effect when targeting individuals with greater risk of nonadherence and when delivering the intervention that maximizes participant convenience and provides enhanced adherence support. Further investigation is needed to assess the postintervention effect and cost-effectiveness of DOT-HAART.
Authors: Grace E Macalino; Joseph W Hogan; Jennifer A Mitty; Lauri B Bazerman; Alison K Delong; Helen Loewenthal; Angela M Caliendo; Timothy P Flanigan Journal: AIDS Date: 2007-07-11 Impact factor: 4.177
Authors: Jean B Nachega; Amy R Knowlton; Andrea Deluca; Jan H Schoeman; Linda Watkinson; Anne Efron; Richard E Chaisson; Gary Maartens Journal: J Acquir Immune Defic Syndr Date: 2006-12-01 Impact factor: 3.731
Authors: Mindy Ma; Billy R Brown; Melissa Coleman; Jeffrey L Kibler; Helen Loewenthal; Jennifer A Mitty Journal: AIDS Patient Care STDS Date: 2008-02 Impact factor: 5.078
Authors: James C M Brust; Alain H Litwin; Karina M Berg; Xuan Li; Moonseong Heo; Julia H Arnsten Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Rajesh C Dash; James A Robb; David L Booker; Wen-Chi Foo; David L Witte; Lynn Bry Journal: Arch Pathol Lab Med Date: 2012-06 Impact factor: 5.534
Authors: S S Solomon; M S Sulkowski; P Amrose; A K Srikrishnan; A M McFall; B Ramasamy; M S Kumar; S Anand; D L Thomas; S H Mehta Journal: J Viral Hepat Date: 2017-08-14 Impact factor: 3.728
Authors: Megan M McLaughlin; Molly F Franke; Maribel Muñoz; Adrianne K Nelson; Olga Saldaña; Janeth Santa Cruz; Milagros Wong; Zibiao Zhang; Leonid Lecca; Eduardo Ticona; Jorge Arevalo; Eduardo Sanchez; Jose Luis Sebastián; Sonya Shin Journal: AIDS Behav Date: 2018-01
Authors: Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner Journal: AIDS Date: 2015-05-15 Impact factor: 4.177